Drug-eluting Balloon Catheters Market Size & Share 2025 – 2034

Drug-eluting Balloon Catheters Market Size

The global drug-eluting balloon catheters market size was valued at USD 637.8 million in 2024 and is expected to exhibit growth at a CAGR of 9.9% from 2025 – 2034 period. The growing incidence of peripheral and cardiovascular diseases, a shift in preference towards non-invasive procedures, and the expanding elderly population, among other factors, can explain high market growth.

The global burden of cardiovascular diseases (CVDs), which includes coronary artery disease, strokes, and peripheral artery disease (PAD), has worsened owing to aging, sedentary lifestyle, and diabetes along with hypertension. For instance, cardiovascular diseases are the number one killer across the globe, which the CDC estimates caused around 19 million deaths in 2021. In the U.S. alone, heart disease accounted for 702,880 deaths in 2022, which is about one in every five deaths.

As a result, the demand for non-invasive solutions, such as the drug-eluting balloon (DEB) catheter, is on the rise. DEB catheters have a distinct advantage in treating arterial blockages and improving blood flow because they do not require a permanent implant. These catheters are becoming the standard for complex lesions where stents are sometimes ineffective in treating.
 

Moreover, the treatment of hyperplasia is aided by drug-eluting balloon catheter or drug-coated balloon catheters. The catheter is infused with an antiproliferative medicine, usually either sirolimus or paclitaxel, and the balloon aids in expanding the artery walls so that the medicine can be located. Moreover, it also provides controlled medication delivery to treat cardiovascular or peripheral problems.
 

Drug-eluting Balloon Catheters Market Trends

Transmitters of DEB catheter technology such as the drug, catheter, and its construction material have undergone numerous innovations leading to marked improvements in the treatment of vascular blockages in patients that suffer from coronary through or peripheral artery disease. These changes appear to be attractive to medical professionals looking for better, less invasive options, and this increases the range of applications for DEB catheters in the field.
 

• One of the most notable improvements has been the drug coatings used for the DEB catheter. Coatings based on sirolimus and paclitaxel allow depositing therapeutic agents onto arterial walls effectively, which limits exposure to wider systems and lowers chances for negative effects.
   
• Improvements in drug-coating technology guarantee that the therapeutic agents are placed exactly where they are needed, at the blockage site, thereby achieving the goal of lowering restenosis rates and enhancing long-term arterial patency. These innovations have made DEB catheters a dependable option for patients suffering from complicated vascular diseases.
   
• In addition, the most recent designs of the DEB catheters are being shaped for simplicity and movement, and hence, are easier to control in a variety of vascular systems. These devices can now be applied to narrower and more complex blood vessels as they are more manoeuvrable and have a smaller catheter diameter. This means that previously challenging cases can now be addressed. The design improvements made have increased the availability of DEB catheters to patients with advanced vascular occlusions because successful treatment can now be done in situations that older technology would not have dealt with.
   

Drug-eluting Balloon Catheters Market Analysis

Based on product, the market is classified into coronary artery disease drug-eluting balloon catheters and peripheral vascular disease drug-eluting balloon catheters. The peripheral vascular disease drug-eluting balloon catheters segment generated the highest revenue of USD 353 million in 2024.
 

• The PVD-DEB catheters are specifically helpful for lesions that are long and diffuse since traditional methods of treating such blockages through stents are inadequate. Certain therapeutic agents are released from the DEB catheters of PVD that reduce the probability of smooth muscle cell growth and elimination so that sufficient blood flow can be provided and better health outcomes achieved when treating the lesions. As the PVD-DEB catheters are more efficient when dealing with complex problems, they have been adopted more frequently while treating patients suffering from peripheral vascular disease, aiding the market share significantly.
   
• The more progressive healthcare providers are steering towards minimally invasive techniques for PVD as it reduces recovery period, complication rates, and increases the comfort of the patient. The use of drug-eluting balloon catheters has proven suitable for these treatment goals, as they offer physical expansion and local drug delivery while eliminating the need for a permanent implant. DEB catheters are widely accepted for PVD, which is why they continue to have a high market share in the segment.
   

Based on material, the drug-eluting balloon catheters market is classified into polyurethane, nylon, and other materials. The polyurethane segment accounted for USD 225.4 million in market revenue in 2024 and is anticipated to grow at a CAGR of 10.4% between the 2025 – 2034 period.
 

• Considering DEB catheter utilization, polyurethanes are multi-functional soft elastic and soft biomaterials. They can easily be shaped and changed to improve flexibility, strength, and resistance to abrasion, allowing for effortless passage through complex vascular regions and enhancing patient experience.
   
• These qualities also make the risk of injury to the vasculature during procedures minimal, which is why polyurethane based catheters are most used in a range of vascular interventions from peripheral to coronary uses.
   
• Thus, the durability and abrasion resistance of polyurethane is critical for DEB devices since they have to withstand being implanted and still be able to deliver drugs to the vascular walls. These catheters must travel through narrow and twisted pathways in the body, which makes them more prone to being eroded at the surface of the catheters.
   
• Since abrasion resistance is an attribute of polyurethanes, these DEB catheters can withstand harsh anatomical locations and repeated uses, which increases the reliability and longer lifespan of the catheters.
   

Based on end use, the drug-eluting balloon catheters market is segmented into hospitals and clinics, ambulatory surgical centers, and catheterization laboratories. The hospitals and clinics segment dominated the market in 2024 and is anticipated to reach USD 938.3 million by the end of the forecast period.
 

• The main reason for this high share is largely attributed to the rising number of chronic diseases that need surgical procedures to be corrected, rises in peripheral and cardiovascular illness, and total number of admissions into the hospitals. Hospitalizations for catheterization procedures in adult patients are primarily driven by peripheral artery diseases.
   
•  For instance, a report by Frontiers on Cardiovascular Epidemiology and Prevention stated that in 2022, more than 238 million people around the globe suffered from peripheral artery disease, which is one of the major causes of death in the world.
   
• In addition, increased use of drug-eluting balloon catheters in clinics and hospitals has been driven by this increased prevalence. Other factors that are favorably propelling the growth of the hospitals and clinics segment include the increase in the need for non-invasive surgical procedures, better healthcare services, escalated surgical lessen, and the highly competitive nature of healthcare professionals.
   

North America drug-eluting balloon catheters market accounted for USD 272.2 million in market revenue in 2024 and is anticipated to grow at a CAGR of 8.4% between the 2025 – 2034 period.
 

• Some of the factors that have contributed to North America's significant share in the world drug-eluting balloon (DEB) catheters market is its developed healthcare system, high cardiovascular disease burden, and strong awareness for these procedures. There is a high rate of peripheral artery disease (PAD) and coronary artery disease (CAD) in the U.S. Thus, there is a greater need for DEB catheters.
   
• Moreover, the technology of drug-eluting balloon has been quickly accepted by the medical practitioners in North America because it promotes the effective delivery of drugs while significantly minimizing adverse events related to its use as compared to the use of traditional stents. Additionally, many clinical trials conducted in the region have supported the efficacy of DEB catheters, which has facilitated their use by interventional cardiologists and vascular surgeons.
   

France drug-eluting balloon catheters market is projected to grow remarkably in the coming years.
 

• The French Healthcare Authority is concerned with the use of minimally invasive treatment, and therefore, the DEB catheters are an excellent option for management of intricate vascular occlusions especially when stenting is not the procedure of choice.
   
• Moreover, increasing investment in the treatment and research of cardiovascular diseases in France has increased the chances of DEB technology application and DEB's catheter development and usage. France is a key investor in the European market for DEB catheters due to the highly advanced healthcare system and increased sensitization of the healthcare givers in the country.
   

Japan holds a dominant position in the Asia Pacific drug-eluting balloon catheters market.
 

• Japanese people are ranked among the countries with highest populations of elderly individuals making the country heavily burdened with peripheral and coronary artery diseases. The treatment of above-mentioned disease using DEB catheter is a less invasive technique and is found to be very effective for older adults who cannot undergo surgery due to increased chances of complications.
   
• The DEB technology is gaining traction among Japanese healthcare providers. The emphasis by the Japanese government on quality healthcare access and advanced treatments is further propelling the growth of the market. The support for medical device innovation within Japan allows faster approvals for regulations, enabling increased market adoption of DEB catheters.
   

Drug-eluting Balloon Catheters Market Share

The market has always been active, and it is becoming even more so with the presence of large multinationals such as B. Braun and Becton, Dickinson and Company and Boston Scientific Corporation investing heavily in innovation and expanding their product portfolios. Important progress is achieved also by regional companies and new entrants especially from Asia Pacific. Ongoing product development is driven by technological innovations such as improvements in vaccine efficacy, safety, and storage and distribution methods. As companies attempt to increase market share and improve their technological base, strategic alliances, mergers, and acquisitions become ordinary.
 

Drug-eluting Balloon Catheters Market Companies

Prominent players operating in the drug-eluting balloon catheters industry include:

• Aachen Resonance GmbH
• B. Braun
• Becton, Dickinson and Company
• Biosensors International
• Biotronik AG
• Boston Scientific Corporation
• Eurocor GmbH
• iVascular S.L.U.
• Lepu Medical Technology(Beijing) Co. Ltd.
• MedAlliance
• Medtronic plc
• Zhejiang Barty Medical Technology Co.Ltd
   

USPs for Top Players:

• Medtronic creates sophisticated drug-eluting catheter balloon systems to perform localized treatment with accuracy and safety.
   
• Boston Scientific makes high performance balloon catheters for efficient drug application with minimal chances of restenosis.
   
• Becton, Dickinson and Company aims to improve adaptability and effectiveness for vascular treatment through innovative designs.
   

Drug-eluting Balloon Catheters Industry News:

• In February 2022, Boston Scientific Corporation acquired Baylis Medical Company Inc. which provides transseptal access solutions, guidewires, sheaths, and balloon dilators that support catheter-based left-heart procedures. This acquisition helped the company expand its geographical presence along with the business revenue by entering new markets.
   
• In March 2021, B. Braun Interventional Systems Inc. (BIS), an affiliate of B. Braun Medical Inc., collaborated with Infraredx, a Nipro Company, to conduct a clinical trial for the B. Braun SeQuent Please ReX Drug-Coated PTCA Balloon Catheter. This collaboration enabled the company to receive U.S. Food and Drug Administration (FDA) approval. It also facilitated the development of long-term global cooperation between the B. Braun Group of Companies and Japan-based Nipro Corporation to advance coronary artery disease management.
   

The drug-eluting balloon catheters market research report includes in-depth coverage of the industry with estimates and forecasts in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Coronary artery disease drug-eluting balloon catheters
  • Paclitaxel
  • Sirolimus
• Peripheral vascular disease drug-eluting balloon catheters
  • Paclitaxel
  • Sirolimus

Market, By Material

• Polyurethane
• Nylon
• Other materials

Market, By End Use

• Hospitals and clinics
• Ambulatory surgical centers
• Catheterization laboratories

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE